JYJeryl Ritzi Tan Yu

Jeryl Ritzi Tan Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeryl Ritzi Tan Yu has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disentangling amantadine response variability in levodopa related dyskinesias: Role of clinical and genetic factors

    by Henry Mauricio Chaparro-Solano, Leila Saadatpour, Jeryl Ritzi T. Yu, Claire Sonneborn, Thiago Peixoto-Leal, Camila C. Piccinin, Saar Anis, Harpreet Kaur, Ekhlas Assaedi, Ignacio F. Mata, et al.

  • Open Access

    Effects of an Inpatient Program on Medication Errors in Hospitalized People with Parkinson's Disease

    by Camila C. Piccinin, Jeryl Ritzi T. Yu, Victoria Stepanyants, Olivia Hogue, Claire Sonneborn, Anne Brooks, Patricia Clark, Shannon Shaffer, Laurie Moser, Tatiana Lopez‐Gonzalez, et al.

    Objective: Hospitalized people with Parkinson's disease (PwP) face increased risks of medication errors and discharge to non‐home settings, both of which are associated with adverse outcomes. This study assessed differences in medication error rates and discharge outcomes before and after implementation of a dedicated inpatient program for hospitalized PwP. Methods: During 2023, a Parkinson's disease (PD) inpatient program was implemented and refined combining: (1) an electronic health record (EHR) census for identification of hospitalized PwP; (2) inpatient monitoring and alignment of inpatient and outpatient regimens by movement‐disorders‐trained advanced practitioners; (3) customized EHR alerts and levodopa orders; (4) pharmacist support, and (5) staff education. Medication error rates and clinical outcomes were compared between January and June 2024 (post‐implementation phase) and a pre‐implementation retrospective cohort from 2018. Results: From January to June 2024, 366 post‐implementation admissions were monitored. Among those receiving contraindicated medications, the median number of doses decreased from 2 (interquartile range [IQR] = 1–6) during pre‐implementation to 1 (IQR: 1–2) post‐implementation ( p = 0.015). Days with a levodopa dose deviation decreased from 43.1% to 38.3%, p < 0.0001, improper levodopa formulation substitutions from 18.6% to 5%, p < 0.0001, timing deviations from 72.2% to 51.8%, p < 0.00001, missed doses from 21.5% to 16.8%, p = 0.013, and discharged to non‐home settings from 44.8% to 38.3%, p = 0.038. Interpretation: Following implementation of a multidisciplinary and proactive inpatient program, reductions in medication errors and improved discharge outcomes were observed among PwP. ANN NEUROL 2026;100:1068–1079

  • Effectiveness, safety, and quality of life outcomes of neurotoxin injections in the treatment of essential tremors: a systematic review

    by Yvanne Joshua C. Rabe, Adrian B. Yu, Jeryl Ritzi T. Yu, David M. Simpson

    Essential tremor (ET) is a chronic, progressive condition classically affecting the hands and arms, is typically bilateral, and may be asymmetric. Tremor related disability can impact mood and quality of life. Disease progression and patient related factors may limit efficacy and use of traditional pharmacologic options. Botulinum neurotoxin (BoNT) injections have been explored as an alternative treatment option. This systematic review aims to evaluate the efficacy and safety of BoNT injections as a therapeutic intervention for essential tremors. Following PRISMA guidelines, a systematic literature search was conducted on PubMed, Cochrane, HERDIN, and ScienceDirect on March 2025. The following search string was used (“Essential tremor” OR “tremor disorder”) AND (“botulinum toxin” OR “neurotoxin” OR “botulinum toxin A” OR “BoNT-B”) AND (“efficacy” OR “safety” OR “treatment”). All articles published prior to March 2025 were included. Of 9121 records, 18 studies were included in the final analysis: eight open label studies, five randomized clinical trials, three retrospective studies, and two prospective crossover studies. The studies looked at ET manifesting as upper limb tremor (n = 12), voice tremor (n = 4), and head tremor (n = 2). Among patients receiving BoNT, majority experienced reduction in tremor amplitude and severity and improvement in quality-of-life. Adverse effects were generally dose-dependent and tolerable. Muscle weakness was reported from injections in the upper limb. Hoarseness, breathiness, coughing/choking, dysphagia, and jaw weakness were mostly reported from injections for voice tremors. Lastly, headache, dizziness and dry skin were reported from injections for head tremors. BoNT injections demonstrated effectiveness in reducing tremor severity and is a promising approach for those experiencing symptoms that are refractory to conventional oral medications. Further controlled trials are necessary to confirm these observations.


  • Parasomnias in movement disorders: a narrative review

    by Paulo L. Cataniag, Jeryl Ritzi T. Yu, Jed Noel C. Ong, Cid Czarina E. Diesta

    Parasomnias are sleep disorders characterized by unusual and often distressing behaviors or experiences that occur during sleep or the transition between wakefulness and sleep. These disorders can arise in both non-rapid eye movement (NREM) and rapid eye movement (REM) sleep stages. REM sleep behavior disorder (RBD) is the most common and most studied parasomnia in movement disorders, especially among synucleinopathies. Numerous researches on RBD have established its clinical significance. Other parasomnias are less frequently reported in movement disorders, making it difficult to draw firm conclusions about their coexistence. Additionally, exploding head syndrome has not yet been documented in any movement disorders. This review summarizes current research on parasomnias, their association with movement disorders, and emphasizes the importance of increased awareness to improve diagnosis, management, and patient outcomes.

  • Therapeutic innovations for the symptomatic treatment of Parkinson’s disease: focus on technology-based therapies

    by Jeryl Ritzi T. Yu, Avery Kundrick, Enrique C. Panganiban, Michelle Ann Sy, Saar Anis, Hubert H. Fernandez

    As Parkinson’s disease (PD) progresses, patients experience motor fluctuations, which may manifest as motor and/or non-motor wearing off symptoms, delayed “ON” time, and/or levodopa-related dyskinesia. Deep brain stimulation (DBS) is an effective therapy but may not be suitable for all patients due to factors such as premorbid conditions age, or accessibility. We review technology-based therapeutic innovations for PD: infusion therapies and novel non-invasive neuromodulation methods using the following databases: PubMed, Cochrane, and Science Direct. Infusion therapies such as percutaneous (LCIG, LECIG) and subcutaneous options (ND0612, foslevodopa-foscarbidopa, CSAI) demonstrate significant benefits in reducing OFF time and enhancing ON time without troublesome dyskinesias. However, vigilance is required for procedural and skin adverse events. Neuromodulation approaches such as auricular, vagus nerve, and galvanic vestibular stimulation, as well as whole-body vibration, showed promising benefits in freezing of gait (FOG) and tremor. Infusion and non-invasive neuromodulation therapies provide additional treatment options for patients with refractory motor and non-motor symptoms and may be an alternative for those who experience limitations of traditional dopaminergic therapies and are not candidates for neurosurgical interventions.


  • Open Access

    Impact of Falls on Quality of Life among Filipinos with Parkinson's Disease from a Referral Center Ambulatory Care PD Clinic

    by Jeryl Ritzi T. Yu, Anna Deborah L. Sarmiento-Santos, Milthon Cua, Michelle J. Tanglao, Raymond L. Rosales


  • Open Access

    Basal Ganglia Syndrome in a Male With an XK Gene Variant but Without XK Disease (McLeod Syndrome)

    by Jeryl Ritzi T. Yu, Ruth H. Walker, Adrian Danek, Connie M. Westhoff, Sunitha Vege, Ilia Itin


  • Open Access

    Optimization of inpatient medication administration among persons with Parkinson’s disease: recommendations on pharmacy technology and workflow

    by Jeryl Ritzi T. Yu, Brent S. Sokola, Benjamin L. Walter

    Individuals with Parkinson’s disease (PD) are vulnerable during hospitalizations due to the underlying complexities o1f symptoms, and acute illness or medication changes often lead to decompensation. Complications during hospitalizations are often due to worsening motor and nonmotor symptoms and commonly result from inaccurate medication regimens. Although the accuracy of medication administration relies on an interplay of factors, including patient status, transitions of care, coordination between the hospital prescriber and outpatient neurologist, etc., hospital pharmacists play an integral role in pharmacotherapy. The main aspects of pharmacy strategies aim to achieve timely administration of levodopa-containing medications, reduction of substitution and omissions of antiparkinsonian medications, and avoidance of antidopaminergic medications. This paper highlights critical areas for improvement and recommendations to minimize the impact of other factors from the pharmacy standpoint.


  • Electronic health record tools as a potential resource for improving care among hospitalized people with Parkinson's disease

    by Camila C. Piccinin, Jeryl Ritzi T. Yu, Anne Brooks, Patricia Clark, Shannon Shaffer, Brent S. Sokola, Kim Lewin, John-Paul Whitman, Scott A. Sperling, Hubert H. Fernandez, et al.